The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A prospective study of neurofibromatosis type 1 cancer incidence in the UK
Open accessAbstract
Neurofibromatosis type 1 (NF1) is an autosomal dominant condition affecting around one in 3000 live births. The manifestations of this condition are extremely variable, even within families, and genetic counselling is consequently difficult with regard to prognosis. Individuals with NF1 are acknowledged to be at increased risk of malignancy. Several studies have previously attempted to quantify this risk, but have involved relatively small study populations. We present prospective data from 448 individuals with NF1 with a total of 5705 years of patient follow-up. These data have been collected via the UK NF1 association for patients. Demographic information on the affected individuals was cross-referenced with UK cancer registry data by the UK Office of National Statistics. The overall risk of cancer was 2.7 times higher in this cohort of NF1 patients than in the general population (95% confidence interval (CI) 1.9-3.7). The cumulative risk of a malignancy by age 50 years was 20% (95% CI 14-29%); beyond this age, the risk of cancer was not significantly elevated (P=0.27). The most frequent types of cancer were connective tissue (14% risk by age 70, 95% CI 7.8-24%) and brain tumours (7.9, 95% CI 3.9-16%). There was no statistically significant excess of cancers at other sites (P=0.22).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
Long-Term Follow-up of von Recklinghausen Neurofibromatosis
Sørensen, S. A., Mulvihill, J. J., & Nielsen, A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604173141603 · Cited by 617
Cited by
Gutmann, D. H., Ferner, R. E., Listernick, R. H., Korf, B. R., Wolters, P. L., & Johnson, K. J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.4 · Cited by 862
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
Daly, M. B., Pilarski, R., Berry, M., Buys, S. S., Farmer, M., Friedman, S., Garber, J. E., Kauff, N. D., Khan, S., Klein, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0003 · Cited by 650
McNeill, K. A. (2016) · Neurologic Clinics · doi:10.1016/j.ncl.2016.06.014 · Cited by 531
Clinical and genetic aspects of neurofibromatosis 1
Jett, K., & Friedman, J. M. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181bf15e3 · Cited by 501
Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1
Uusitalo, E., Rantanen, M., Kallionpää, R. A., Pöyhönen, M., Leppävirta, J., Ylä-Outinen, H., Riccardi, V. M., Pukkala, E., Pitkäniemi, J., Peltonen, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.3576 · Cited by 418
Metadata
- Authors
- Walker, L., Thompson, D., Easton, D., Ponder, B., Ponder, M., Frayling, I., & Baralle, D.
- Venue
- British Journal of Cancer
- Published
- 2006-06-20
- Volume
- 95
- Issue
- 2
- Pages
- 233-238
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2066209628
- Cited by
- 240
- References
- 2
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A prospective study of neurofibromatosis type 1 cancer incidence in the UK. https://app.cochat.ai/papers/10.1038/sj.bjc.6603227
- The paper
- Walker, L., Thompson, D., Easton, D., Ponder, B., Ponder, M., Frayling, I., & Baralle, D. (2006). A prospective study of neurofibromatosis type 1 cancer incidence in the UK. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6603227
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.